Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 50 21 versus LO BLISOVI FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 50 21 versus LO BLISOVI FE.
DEMULEN 1/50-21 vs LO-BLISOVI FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
None Documented
None Documented
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Terminal elimination half-life: 15-18 hours for ethinyl estradiol; clinical context: supports once-daily dosing
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Renal (approximately 60% as metabolites, 10-15% as unchanged drug); fecal (about 20-30%)
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive